Pfizer could potentially use its newfound firepower to buy a company as large as Bristol-Myers Squibb Co, a $92-billion market capitalization cancer drugmaker that fueled takeover speculation after a disappointing drug trial in August sent its stock down more than 25 percent. Bristol-Myers Squibb’s blockbuster cancer drug Opdivo could compliment Pfizer’s plan to become a leader in immuno-oncology, which seeks to use the body’s own defenses to treat cancer, industry bankers said, without suggesting that any deal is in the works. Pfizer declined to comment, while Bristol-Myers Squibb did not respond to a request for comment. Another cancer drug company that could attract takeover interest following a cash repatriation is Incyte Corp, as it could make an attractive target for Gilead Sciences Inc if it was able to bring home its nearly $25 billion in overseas cash, bankers said. Gilead has been under pressure to find a new blockbuster because of declining sales from its aging Hepatitis C franchise and the recent failure in clinical trials of a cancer drug that would have competed with Incyte’s successful blood cancer drug, Jakafi. Gilead declined comment; Incyte did not respond to a request for comment. Beyond cancer drug makers, other biotechnology companies that could attract takeover interest include those specializing in neurology companies, such as Acadia Pharmaceuticals Inc, that have promising treatments for ailments such as Alzheimer’s psychosis and migraine. Acadia did not respond to a request for comment. great site“We believe the vast majority of investors have been underweight biotech all year,” said Yee in his note. “A coiled spring of money flow may need to shift back over to biotech.” (Reporting by Carl O’Donnell in New York; Editing by Greg Roumeliotis and Nick Zieminski) Read the original article on Reuters . Copyright 2016.
For the original version including any supplementary images or video, visit http://www.businessinsider.com/r-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12?utm_source=feedburner&utm_medium=referral
That total includes his base salary, bonuses, stock awards and other compensation over 10 years. Trump has made no secret of his desire to be friendly with the oil industry. The president-elect wants to unleash the country’s natural resources by rolling back drilling regulations and drilling on federal lands. “America’s incredible energy potential remains untapped,” Trump said in a May speech, adding that the problem is “totally self-inflected.” Related: Donald Trump’s curious Goldman Sachs connections Trump, who ran for president as a populist outsider who promised to “drain the swamp” in Washington, has so far nominated other ultra-wealthy people for his cabinet. Among the richest nominees so far are billionaires Wilbur Ross for secretary of commerce and Betsy DeVos for secretary of education. Trump’s pick for deputy secretary of commerce, Todd Ricketts, is the son of a billionaire and co-owns the Chicago Cubs. browse this siteHis would-be Treasury secretary is former Goldman Sachs ( GS ) banker and Hollywood bankroller Steven Mnuchin . Chief strategist Steve Bannon also worked as a Goldman Sachs banker before serving as chairman of Breitbart News. Whether he goes to the Trump administration or not, ExxonMobil is poised to lose Tillerson at a critical time. Feeling the effects of low oil prices, Exxon is currently facing a long slump . Its U.S.
For the original version including any supplementary images or video, visit http://money.cnn.com/2016/12/06/news/tillerson-trump-secretary-state-exxonmobil/index.html?section=money_topstories
You may also be interested to read
- more tips here
- click resources
You may also be interested to read
- why not try these out
- check my source